Proxima Fusion raises €130M Series A to build world’s first stellarator-based fusion power plant in the 2030s

Balderton

Europe’s fastest-growing fusion company unlocks funding to advance commercial fusion technology and secure energy resilience for the continent.

Proxima Fusion, Europe’s fastest-growing fusion energy company, today announced the close of its €130 million ($150 million) Series A financing — the largest private fusion investment round in Europe. The Series A financing was co-led by Cherry Ventures and Balderton Capital, with participation from several other strategic investors.

This brings Proxima Fusion’s total funding to more than €185 million ($200 million) in private and public capital, accelerating its mission to build the world’s first commercial fusion power plant based on a stellarator design.

Fusion has become a real, strategic opportunity to shift global energy dependence from natural resources to technological leadership. Proxima is perfectly positioned to harness that momentum by uniting a spectacular engineering and manufacturing team with world-leading research institutions, accelerating the path toward bringing the first European fusion power plant online in the next decade.

Francesco SciortinoCEO and co-founder, Proxima Fusion

Proxima was founded in April 2023 as a spin-out from the Max Planck Institute for Plasma Physics (IPP), with which it continues to work closely in a public-private partnership to lead Europe into a new era of clean energy. The EU, as well as national governments including Germany, UK, France and Italy, increasingly recognise fusion as a generational technology essential for energy sovereignty, industrial competitiveness, and carbon-neutral economic growth.

By building on Europe’s long-standing public fusion investment and industrial supply chains, Proxima Fusion is laying the groundwork for a new high-tech energy industry—one that transforms the continent from a leader in fusion research to a global powerhouse in fusion deployment.

Proxima is taking a simulation-driven approach to engineering that leverages advanced computing and high-temperature superconducting (HTS) technology to build on the groundbreaking results of the IPP’s Wendelstein 7-X stellarator experiment.

Just earlier this year, together with the IPP, KIT and other partners, Proxima unveiled Stellaris. As the first peer-reviewed stellarator concept to integrate physics, engineering, and maintenance considerations from the outset, Stellaris has been widely recognized as a major breakthrough for the fusion industry, advancing the case for quasi-isodynamic (QI) stellarators as the most promising pathway to a commercial fusion power plant.

Stellarators aren’t just the most technologically viable approach to fusion energy—they’re the power plants of the future, capable of leading Europe into a new era of clean energy. Proxima has firmly secured its position as the leading European contender in the global race to commercial fusion. We are thrilled to partner with Proxima’s game-changing team of engineers, alongside Europe’s top manufacturers, to build a company that will be transformational for Europe.

Daniel WaterhousePartner, Balderton

With this new funding, the company will complete its Stellarator Model Coil (SMC) in 2027, a major hardware demonstration that will de-risk high-temperature superconductor (HTS) technology for stellarators and stimulate European HTS innovation. Proxima will also finalize a site for Alpha, its demonstration stellarator, for which it is in talks with several European governments already. Alpha is scheduled to begin operations in 2031, and is the key step to demonstrating Q>1 (net energy gain) and moving towards a first-of-a-kind fusion power plant. The company will continue to grow its 80+-strong team across three offices: at the headquarters in Munich, at the Paul Scherrer Institute near Zurich (Switzerland), and at the Culham fusion campus near Oxford (UK).

Fusion energy is entering a new era—moving from lab-based science to industrial-scale engineering. This investment validates our approach and gives us the resources to deliver hardware that is essential to make clean fusion power a reality.

Dr Francesco SciortinoCEO & co-founder, Proxima Fusion

Categories: News

Tags:

PlayMetrics and Stack Sports Combine to Create Leader in Sports Software

Merger unites two industry innovators to meet customers’ evolving preferences and ushers in a new era for sports technology


RALEIGH, N.C., & DALLAS, JUNE 11, 2025—PlayMetrics, a leading provider of operations management software for youth sports organizations, and Stack Sports, a global technology leader for the sports industry, today announced their merger, creating a best-in-class platform in the sports management technology ecosystem. This strategic combination unites two highly complementary and trusted brands, augmenting PlayMetrics’ modern technology platform with the scale, reach, and capabilities of Stack Sports to better serve the evolving needs of sports organizations worldwide. Michael Doernberg, CEO of PlayMetrics, will lead the combined organization as CEO, and Jeff Young, CEO of Stack Sports, will transition to a strategic role as advisor to the board of directors.

Genstar Capital, a leading private equity firm, supported the combination and will be the majority owner of the combined company. As part of the transaction, Genstar acquired PlayMetrics from Blue Star Innovation Partners (“BSIP”), which had been the company’s lead investor since 2023.

PlayMetrics helps customers streamline and modernize every facet of their operations, serving over 2,700 youth sports organizations across a variety of sports. Following a successful expansion beyond its flagship club operating system into governing bodies, leagues, and tournaments – including the acquisition of Crossbar in 2023 – PlayMetrics has experienced unprecedented levels of growth and customer retention over the last few years. Stack Sports is a global technology leader in SaaS platform offerings for the sports industry.

“Sports organizations are increasingly seeking a single, cohesive platform to manage their daily operations and complex business needs,” said Mr. Doernberg. “PlayMetrics has been transformational in delivering a one-stop solution for members, coaches, directors, and administrators. By joining forces with Stack Sports, we further enhance our ability to serve our customers with innovative, reliable, and intuitive software.”

“This merger marks an exciting new chapter for the sports technology industry,” said Mr. Young. “We have long admired the PlayMetrics brand, and by combining our strengths, we will accelerate the speed at which new products are released, customer service is delivered, and industry relationships are forged.”

“The combination of PlayMetrics and Stack Sports creates one of the largest sports technology platforms delivering comprehensive, market-leading solutions to clubs, leagues, tournaments, state associations, and governing bodies,” said Eli Weiss, Managing Partner of Genstar. “We are thrilled to support this transformative combination.”

“We are incredibly proud of what the PlayMetrics team has accomplished under Mike’s visionary leadership,” said Dan Wechsler, CEO of BSIP. “Together, we transformed PlayMetrics from a promising software platform into a market leader in sports management technology, delivering significant value for our investors and customers. Mike and his team’s dedication to innovation and customer success were key drivers, and we wish them all the best as they embark on their next chapter.”

Ropes & Gray acted as legal counsel and Lazard acted as financial advisor to Genstar. Weil, Gotshal & Manges LLP acted as legal counsel and William Blair acted as financial advisor to BSIP.

About PlayMetrics

PlayMetrics, the most user-friendly and intuitive Operating System in youth sports, is purpose-built to simplify the unique complexities of running a club, league, tournament, or governing body. Trusted by forward-thinking leaders across a variety of sports, PlayMetrics empowers directors, coaches, administrators, and player families to modernize their daily operations with unified financial, operational, coaching, and communication tools. Learn more at https://home.playmetrics.com/.

About Stack Sports

Stack Sports provides world-class software and services to support national governing bodies, youth sports associations, leagues, clubs, parents, coaches, and athletes. Some of the largest and most prominent sports organizations, including the U.S. Soccer Federation, Little League Baseball and Softball, and Pop Warner Little Scholars, rely on Stack Sports technology to run and manage their organizations.

Stack Sports is headquartered in Dallas and is leading the industry one team at a time focusing on four key pillars — Grassroots Engagement, Participation Growth, Recruiting Pathways, and Elite Player Development. To learn more about how Stack Sports is transforming the sports experience, please visit https://stacksports.com/.

About Genstar Capital

Genstar Capital (www.gencap.com) is a leading private equity firm that has been actively investing in high-quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar currently has approximately $50 billion of assets under management and targets investments focused on targeted segments of the financial services, software, healthcare, and industrials industries.

About Blue Star Innovation Partners

Blue Star Innovation Partners is a Dallas, Texas based growth equity firm built by founders, for founders. Our team brings decades of experience scaling software, payments, and fintech businesses, giving us a unique advantage on the challenges and opportunities that founders face. We’re currently investing out of our third fund, leveraging our proven track record to help management teams accelerate growth and build category leaders. Learn more at https://www.bsipgp.com/.

Contacts

For Genstar, PlayMetrics, or Stack Sports:
FGS Global
GenstarCapital@fgsglobal.com

For Blue Star Innovation Partners:
Info@bluestarinnovationpartners.com

Categories: News

Tags:

ABN AMRO announces EUR 10m commitment to Keen Venture Partners’ European Defence and Security Tech Fund

Keen
  • This investment is ABN AMRO’s first investment in a dedicated European defence fund
  • The Fund targets early-stage companies across the EU, focusing on information superiority, cyber defence, space, autonomy and robotics among others
  • This investment aligns with the ABN AMRO’s strategy to strengthen European security and defence amid geopolitical challenges

In light of increased international tension and conflicts, Russia’s invasion of Ukraine in 2022, and recent pressure on the Atlantic alliance, Europe has been forced to reassess its military defence strategy and expenditure. ABN AMRO has stepped up its support to the security and defence industry in 2025, widening the scope of defence and security projects eligible for banking products, while closely keeping track of emerging defence technologies.

Keen’s European Defence and Security Tech Fund, with a focus on early-stage companies within the defence and security technology sector, aims to support companies that are provide ‘dual use’ solutions in areas such as information superiority, cyber defence, robotics, AI, autonomous systems and space technologies such as securing satellite communications, satellite image analysis, and defence of space assets. The fund’s investments will be pan-European, with exposure to the United Kingdom, Turkey and Norway.

Dan Dorner, ABN AMRO’s Chief Commercial Officer Corporate Banking said: “ABN AMRO today announces a pioneering effort to enhance the availability of capital for defence-focused ventures in Europe, with a €10 million commitment to Keen’s European Defence and Security Tech Fund. Our commitment aligns with ABN AMRO’s Corporate Banking support to the European defence industry.”

Alexander Ribbink and Giuseppe Lacerenza, Partners at Keen Venture Partners: ‘The team at Keen has a long commitment to and investments in defence and defence technology. The opportunity to add the power of tech entrepreneurs with the full support of venture capital to the European defence ecosystem is huge. A stronger and safer Europe needs the resourcefulness and grit that only entrepreneurs can bring. We are proud to be at the forefront of this trend, and to be supported by ABN AMRO’.

More information:

Keen Venture Partners is a radically human venture capital firm based in Amsterdam and London. Keen backs exceptional teams and fast-growing European tech companies from seed to Series B. Keen has built strong expertise in defence and deep tech, supported by an advisory board of European military leaders, industry veterans, and policymakers. The firm invests through a thesis-driven approach, formulating investment ideas based on fundamental trends in specific areas of technology. When getting to know founders, Keen shares its network of operators, experience, and capabilities even before investing. The portfolio consists of 30+ startups and scaleups across Europe. You can find more information at: www.keenventurepartners.com.


ABN AMRO Corporate Investments offers ABN AMRO clients an opportunity to help accelerate the transition to a resilient and sustainable society through a comprehensive array of capital products. These include amongst others fund investments & co-investments, direct investments through the Sustainable Impact Fund (one of the largest private impact funds in the Netherlands), hybrid debt and sub-ordinated debt.

Categories: News

Tags:

EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio

eqt

Neuron Signal Transfer original 1172027

  • inancing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors
  • Proceeds will support the Phase 1/2 clinical development of lead program SB-007 in Stargardt disease, a genetic eye disorder that causes progressive vision loss and blindness
  • Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other therapeutic areas

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in SpliceBio. The Spanish biotech company is developing novel therapies for genetic diseases – including ophthalmology, neurology, and other therapeutic areas – by leveraging an innovative intein platform. The platform allows large genes to be split into smaller pieces, delivered separately, and then reassembled to create full-length proteins needed to treat diseases.

The USD 135 million Series B financing round will help fund the Phase 1/2 clinical trial of SpliceBio’s lead gene therapy candidate, SB-007, which is being developed to treat Stargardt disease. The round was co-led by EQT Life Sciences and Sanofi Ventures, with participation from new investor Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.

Stargardt disease, which leads to progressive vision loss and blindness, is the most commonly inherited condition causing degeneration in the macula, affecting 1 in 8,000-10,000 people. Currently, there are no approved treatments available for Stargardt disease. The disease is caused by mutations in the ABCA4 gene, which result in a dysfunctional ABCA4 protein. SpliceBio’s SB-007 uses an innovative Protein Splicing technology, based on a family of proprietary engineered proteins called inteins, originally developed at Princeton University. The approach overcomes the challenge of the ABCA4 gene that is too big for traditional gene therapy delivery methods, thereby enabling the production of a healthy ABCA4 protein directly in the retina. 

This approach has the potential to benefit the entire addressable patient pool, regardless of which of the more than 1,200 known mutations responsible for causing Stargardt disease patients carry. Crucially, the difficulty of delivering large genes is also a common barrier in treating many other genetic disorders, highlighting the broad potential and versatility of SpliceBio’s technology beyond Stargardt disease.

“This financing marks a pivotal milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and continue to expand our pipeline across ophthalmology, neurology, and beyond,” said Miquel Vila-Perelló, Chief Executive Officer and Co-Founder of SpliceBio. “The support from such high-quality investors underscores the strength of our programs and our unique Protein Splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today. We are building a company positioned to lead the next wave of genetic medicines.”

Daniela Begolo, Managing Director at EQT Life Sciences who will join the SpliceBio Board of Directors, commented: “We are proud to support SpliceBio, a pioneer among the next generation of genetic medicine companies. Its Protein Splicing platform offers a novel solution to deliver large genes, one of the field’s most pressing challenges, and exemplifies our commitment to backing science that transforms patients’ lives.”

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.

More information: https://eqtgroup.com/private-capital/eqt-life-sciences

About SpliceBio 
SpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. The Company’s lead program, SB-007, targets the root cause of Stargardt disease, a genetic eye disease that causes blindness in children and adults. SpliceBio’s pipeline comprises additional gene therapy programs across therapeutic areas, including ophthalmology and neurology. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein, Protein Splicing, and protein engineering research. For additional information, please visit www.splice.bio

Categories: News

Tags:

XRobotics’ raises $2.5M as countertop robots cooks up 25,000 pizzas a month

SOSV

In the fast-paced world of food service, speed and consistency can make or break a business. That’s why XRobotics believes it’s cracked the code on how to bring robotics into everyday restaurants – starting with pizza. And they’ve just announced a $2.5 million seed round led by FinSight Ventures with participation from SOSV, MANA Ventures, and Republic Capital.

The San Francisco-based company has built a compact countertop robot called the xPizza Cube. About the size of a stackable washing machine, the device uses ML to apply sauce, cheese, and pepperoni to pizza dough with speed and precision. It can crank out up to 100 pizzas per hour and adapt to a variety of styles, including Chicago deep dish and Detroit square.

The economics are compelling: the machine leases for $1,300/month over three years and retrofits into existing kitchens, making it accessible to national chains as well as mom and pop shop owners.

“This saves almost 70, sometimes 80% of the time for the staff,” says co-founder and CEO Denis Rodionov. “It is just repeatable work. If you have a pepperoni pizza, you need to place 50 slices of pepperoni one by one.” The robot does that for you, perfectly, every time.

Kira Colburn

Categories: News

Tags:

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

GIlde Healthcare
  • Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors 
  • Proceeds will support clinical development of lead program SB-007 in Stargardt disease  
  • Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other undisclosed therapeutic areas  

 

SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.

The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and the observational POLARIS study. SB-007 is the first dual adeno-associated viral (AAV) gene therapy cleared by the Food and Drug Administration (FDA) to enter clinical development for Stargardt disease. SB-007 has also received regulatory clearance for clinical development from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene that leads to progressive vision loss and blindness, with no approved treatments available. SB-007 is designed to address the underlying genetic cause of the disease by producing a functional copy of the full-length ABCA4 protein with the potential to treat all patients, regardless of their specific ABCA4 mutation. The proceeds will also be used to accelerate SpliceBio’s pipeline of AAV gene therapy programs in ophthalmology, neurology, and other undisclosed indications that utilise the company’s proprietary Protein Splicing platform.

“This financing marks a pivotal milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and continue to expand our pipeline across ophthalmology, neurology and beyond,” said Miquel Vila-Perelló, Ph.D., Chief Executive Officer and Co-Founder of SpliceBio. “The support from such high-quality investors underscores the strength of our programs and our unique Protein Splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today. We are building a company positioned to lead the next wave of genetic medicines.”

SpliceBio is redefining and expanding the scope of diseases that can be tackled with gene therapies by addressing a fundamental limitation of AAV vectors in their inability to deliver genes that exceed their limited packaging capacity of 4.7 kilobases. Many genetic disorders remain untreatable because the necessary gene is too large to fit into the AAV vectors. SpliceBio’s unique Protein Splicing platform leverages the use of a family of proprietary, engineered proteins called inteins, originally developed at Princeton University. The company’s technology enables the splitting of the gene into two (or more) transgenes that are then delivered using dual AAV vectors. Once inside the cell, the DNA of each transgene is transcribed into messenger RNA and translated into protein. SpliceBio’s engineered inteins are designed to then assemble the full-length protein that is needed to treat the disease.

About SpliceBio 
SpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. The Company’s lead program, SB-007, targets the root cause of Stargardt disease, a genetic eye disease that causes blindness in children and adults. SpliceBio’s pipeline comprises additional gene therapy programs across therapeutic areas, including ophthalmology and neurology. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein, Protein Splicing, and protein engineering research. For additional information, please visit www.splice.bio.

About SB-007 
SB-007 is an investigational Protein Splicing dual AAV gene therapy in development for the treatment of Stargardt disease. It is designed to restore expression of the native full-length ABCA4 protein in the retina. SB-007 has been granted Orphan Drug Designation from both the FDA in the US and the European Commission in Europe. In December 2024, SB-007 received FDA IND clearance, marking the first-ever clearance for a dual AAV gene therapy in Stargardt disease. Alongside initiation of the Phase 1/2 ASTRA study, with the announcement of the first patient dosed in March 2025, SpliceBio continues to advance POLARIS, a natural history study of the disease. Both studies are actively recruiting. For more information or to enquire about participation in the studies, please visit www.splice.bio/clinical.

About Gilde Healthcare 
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Nordic Capital to partner with Minerva Imaging, to support its growth journey in the radiopharmaceutical space

Nordic Capital

The investment will be made in close partnership with the founders of Minerva, marking a joint commitment to seek to accelerate the company’s growth, international expansion and further strengthening its integrated platform and service offerings, with the ambition of building a global market-leading radiopharmaceutical platform.

Minerva Imaging (“Minerva”) is a market-leading, science-driven Contract Research Organisation (“CRO”) and Contract Development and Manufacturing Organisation (“CDMO”), specialising in the development of targeted radioligand therapies — a fast-emerging and transformative field within cancer therapeutics. The partnership will support Minerva’s growth journey and ambition to build a global market-leading radiopharmaceutical platform

With deep expertise in molecular imaging and advanced oncology and cardiovascular disease models, Minerva delivers a highly differentiated, fully integrated platform that combines scientific excellence with end-to-end service capabilities. The company partners with many of the world’s leading pharmaceutical and biotechnology companies and is widely recognised for its industry-leading expertise and best-in-class capabilities. Today, Minerva employs over 150 highly skilled professionals, including a significant number of PhD-level scientists. The company has experienced rapid growth in recent years, generating revenue of more than DKK 225 million in 2024.

The global radiopharmaceuticals market is expected to be poised for significant growth over the next decade, driven by the increasing incidence of cancer and a growing demand for precision medicines. Through its partnership with Nordic Capital, Minerva is well-positioned to scale its operations and enhance its scientific capabilities, which would enable the company to provide even greater support to its customers throughout the pre-clinical and clinical development process.

“We are incredibly proud of Minerva’s progress since its founding. Our innovative solutions are making a meaningful impact for our collaborators and customers, with the ultimate goal of helping patients. We look forward to continuing this journey together with Nordic Capital, which brings extensive expertise, a strong network, and the capital needed to support our next phase. Their support enables us to work closely with our collaborators to advance the development of novel approaches that benefit patients”, said Andreas Kjaer, Chairman and Founder, Minerva.

“Our mission is to help transform translational research and drug development for patients with an unmet need. Together with Nordic Capital, we can seek to support innovation and boost our growth via organic expansion and potential selective strategic acquisitions. Partnering with Nordic Capital for our next growth phase will enable us to strengthen and extend our integrated service offerings to our valued customers and collaborators”, said Carsten H. Nielsen, CEO and Founder, Minerva.

“Minerva is a frontrunner in its field, and we are deeply impressed by the team and what they have built over the past 15 years. Its rigorous scientific approach and well-established platform positions the company strongly to capture future growth in the radiopharmaceuticals sector. As a leading healthcare investor with deep expertise across pharma, life sciences, and pharma services – and a strong track record in supporting international expansion – we are convinced Nordic Capital is uniquely positioned to support Minerva in its next phase of growth and in broadening its research-to-clinic service offering. We are excited about the opportunity for Nordic Capital to contribute to the next phase of Minerva’s journey as a partner to the founders and management”, said Jonas Agnblad, Partner and Co-Head of Nordic Capital Evolution advisory.

As a leading healthcare investor with over three decades of experience in fostering growth and international expansion, Nordic Capital is primed to support Minerva on its future growth journey. Nordic Capital will leverage its sector and in-house operational expertise together within its expert networks to facilitate continued growth and development. With a total committed capital of EUR 3.2 billion, Nordic Capital’s Evolution platform targets investments in middle-market growth companies across Northern Europe, applying Nordic Capital’s proven sector model. Minerva marks the eleventh investment made by Nordic Capital Evolution since 2021.

It has been agreed that the terms of the transaction shall not be disclosed. Completion of the transaction is expected in Q3 2025 and is subject to customary regulatory approvals and closing conditions.

Media contacts:

Nordic Capital
Katarina Janerud
Communications Manager, Nordic Capital Advisors
+46 8 440 50 50
katarina.janerud@nordiccapital.com

Minerva Imaging
Carsten H. Nielsen
CEO, Minerva Imaging
info@minervaimaging.com

About Minerva Imaging
Minerva Imaging is an integrated CRO and CDMO specialised in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services. www.minervaimaging.com

About Nordic Capital
Nordic Capital is a leading sector-specialist private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and Services & Industrial Tech. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested c. EUR 28 billion in 150 investments. Nordic Capital’s most recent funds are Nordic Capital XI with EUR 9 billion in committed capital and Nordic Capital Evolution II with EUR 2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. www.nordiccapital.com.

Categories: News

Tags:

Bridgepoint partners with NMi Group to accelerate strategic growth

Bridgepoint

Bridgepoint, one of the world’s leading quoted private asset growth investors, has announced it is partnering with NMi Group (“NMi”), a pan-European provider of independent Advisory, Testing, Inspection, Certification, and Calibration (“ATICC”) services.

The transaction sees Bridgepoint Development Capital V – a lower middle-market fund focused on supporting fast-growing businesses across Europe – become the majority shareholder in NMi, with the exit of existing partner Levine Leichtman Capital Partners (“LLCP”). NMi’s management team will reinvest alongside Bridgepoint, ushering in the next chapter of growth for the business.

Founded in 1873, NMi ensures the systems, devices, and services that shape our daily lives – such as electric vehicle (EV) charging infrastructure, smart meters, medical devices, mobile and payment technologies, industrial control systems and safety-critical instrumentation – are accurate, fully compliant and future-ready.

The company has built a leading platform designed to meet the mission-critical demands of clients bringing new and enhanced technologies to market, often in highly regulated environments – supporting clients across the UK, Europe, Asia and the Americas with market access services such as metrology, hazardous environment safety and cyber security certification. The business also provides a range of regulatory-driven in-life services to ensure products remain compliant and accurate throughout their use, including complex calibrations, verification services, and compliance assurance.

With c.300 employees across nine sites, NMi serves over 7,000 clients in high-stakes sectors such as energy and utilities, technology, manufacturing, defence, transport and life sciences. Growth in recent years has been strong, driven by a combination of organic momentum and a disciplined buy-and-build strategy – underpinned by a series of strategic acquisitions since 2020.

NMi operates in a large and expanding global market for market access and in-life services. Growth is fuelled by increasing product complexity, evolving regulations, and rising demand for high-trust, impartial assurance –particularly in cybersecurity, industrial battery energy storage systems (BESS), and connected infrastructure. Anticipated regulatory changes, such as the EU Cyber Resilience Act and ongoing investment in energy transition and smart technologies, are expected to further accelerate demand for NMi’s services.

Bridgepoint will support NMi in scaling its international platform through continued investment in high-growth certifications and adjacent capabilities. The focus will include geographic expansion into regions such as the DACH and Nordic countries, and the development of enhanced commercial infrastructure. With its proven track record of scaling technical services and certification businesses, Bridgepoint will support NMi’s ambition to become a global leader and trusted technical partner in sectors like Energy Transition, Smart Mobility, and Digital Infrastructure.

Bridgepoint has deep ATICC sector experience through investments in companies such as Element Materials Technology, LGC, and Fera Science. Its partnership with NMi builds on this legacy and reinforces Bridgepoint’s strategy of investing in knowledge-led, high-growth businesses, including prior investments in Achilles, Sinari, and Surikat.

Matt Legg, Partner at Bridgepoint, said:

“NMi is a rare and high-quality international ATICC platform with an outstanding reputation for quality and trust, underpinned by a unique heritage and highly technical team. The business offers a compelling combination of sector-leading organic growth with significant further potential for M&A as the acquirer of choice in its space. With rising regulation and complexity across end markets, NMi is well-positioned to become a global leader in market access and in-life compliance services—an ambition we look forward to supporting alongside its management team.”

Yvo Jansen, CEO of NMi Group, added:

“This partnership aligns our long-term strategy with stakeholder needs. Bridgepoint brings deep sector experience and international reach—key as we support clients navigating increasingly complex regulatory landscapes. I’d also like to thank LLCP, who helped us scale with focus and discipline. With that strong foundation, we’re ready for the next stage—with our clients and new partners.

Joanne Spick, CFO, NMi Group, commented:

“As regulatory demands grow, our clients need more than compliance—they need confidence. That means reliable services, smarter systems, and partners who are thinking long-term. With Bridgepoint’s support, we’ll keep investing in capabilities that matter, helping clients stay ahead and scale with assurance.”

Bridgepoint was advised on the transaction by DC Advisory (M&A and debt), Houthoff and Ropes & Gray (Legal), BCG (Commercial), BDO (Financial) and EY (tax). LLCP and NMi were advised by Houlihan Lokey (lead M&A), Rothschild (M&A), Nauta Dutilh (Legal), OC&C (Commercial), PwC (Financial and Tax) and Jamieson (Management).

The transaction is expected to complete in Q3 2025, subject to customary regulatory approvals and works council advice. Financial terms of the transaction were not disclosed.

Categories: News

Tags:

Bridgepoint prices reset of Bridgepoint CLO V

Bridgepoint prices reset of Bridgepoint CLO V

Bridgepoint has today announced the successful pricing of the reset of Bridgepoint CLO V.

The transaction extends the investment period to 2030 and lowers the cost of capital of the original 2023 deal.

Bridgepoint’s third CLO transaction of 2025, the reset saw strong demand throughout the full capital stack, evidencing the market’s continued appetite for Bridgepoint’s disciplined approach to investment and credit selection.

Commenting on the transaction, John Murphy, Partner and Bridgepoint’s Head of Syndicated Debt, said:

“We’re pleased to have seen such strong continued interest from our broader investor base with the reset of Bridgepoint CLO V. By combining a long-term reinvestment horizon with a flexible, high-conviction approach to portfolio management, we’ve shown our platform can adapt to changing markets and unlock consistent value. This robust investor demand speaks to the trust placed in our differentiated approach.”

With more than €14 billion of assets under management in corporate credit across the risk/reward spectrum, Bridgepoint Credit is one of Europe’s most experienced credit managers. It focuses on three complementary investment strategies: Direct Lending, Credit Opportunities and Syndicated Debt.

Categories: News

Tags:

Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

Abingworth

– Spin-out of Scorpion Therapeutics, led by former Scorpion Therapeutics management team –

– Advancing multiple programs across cancer and other serious diseases; plans to advance first new product candidate into the clinic in 2026 –

– Series A financing co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from other leading healthcare funds –

BOSTON, Mass. – June 10, 2025 – Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing. The financing was co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors.

Antares is a spin-out of Scorpion Therapeutics, Inc. (“Scorpion”), which sold its mutant-selective PI3Kα inhibitor program, STX-478, to Eli Lilly and Company (“Lilly”) in March 2025 for up to $2.5 billion in total consideration. Scorpion was founded in 2020 and, in the subsequent five years, raised a total of $420 million in financing, executed partnerships with multiple pharmaceutical companies, and generated six development candidates, three of which are in clinical testing. Antares is led by Scorpion’s former executive leadership team and is advancing a pipeline of small molecule assets developed at Scorpion, including programs in precision oncology and other therapeutic areas, as well as programs initiated through Scorpion’s 2022 transcription factor collaboration with AstraZeneca.

“We took our name from Antares, the brightest star in the Scorpius constellation, and known as ‘the heart of the Scorpion.’ We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fueled by discoveries in drugging previously inaccessible targets,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares and former Chief Executive Officer of Scorpion. “We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need.”

“At Omega, we focus on identifying approaches and working with exceptional teams to deliver impactful products to patients,” said Otello Stampacchia, Ph.D., Founder and Managing Director at Omega Funds. “Antares meets each of these criteria. As one of the founding investors in Scorpion, we have had the opportunity to follow the company’s evolution very closely and have been consistently impressed by the breadth of the team’s capabilities, as well as their scientific rigor and rapid execution. I look forward to seeing the company’s vision advance by delivering differentiated, first-in-class products to treat some of the most important unmet medical needs.”

Additionally, Antares announced that Pierre Fabre Laboratories, with whom Scorpion previously partnered to advance two clinical-stage, highly selective next-generation mutant EGFR inhibitors for the treatment of non-small cell lung cancer, has acquired global rights to both programs. Under the terms of the agreement, Pierre Fabre Laboratories will lead the continued clinical development and global commercialization of both programs, and Antares will be eligible to receive regulatory and commercial milestones and tiered royalties.

Antares’ leadership team

Antares is led by the former Scorpion executive team, including leaders with accomplished track records in the biotechnology industry:

  • Adam Friedman, M.D., Ph.D., Chief Executive Officer
  • Natasja Brooijmans, Ph.D., Executive Vice President, Discovery Predictive Sciences
  • Mark Chao, M.D., Ph.D., Chief Medical Officer
  • Andrew Fedder, General Counsel
  • Angel Guzman-Perez, Ph.D., Executive Vice President, Head of Chemistry
  • Erica Jackson, Ph.D., Chief Scientific Officer
  • Darrin Stuart, Ph.D., Chief Development Officer
  • Amanda Valentino, Chief People Officer

The company’s Board of Directors are industry veterans with company-building expertise, as well as experience pioneering breakthrough medicines:

  • Jeff Albers, J.D., M.B.A., Board Chair at Antares Therapeutics and Venture Partner at Atlas Venture
  • Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners
  • Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School
  • Jean-François Formela, M.D., Partner at Atlas Venture
  • Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares Therapeutics
  • Sir Menelas Pangalos, Ph.D., formerly Executive Vice President of Biopharmaceuticals R&D at AstraZeneca

“After years of investment into its proprietary drug discovery capabilities, the team at Antares has made notable progress to unlock the therapeutic potential of targets long seen as important – but undruggable – like the large class of transcription factors,” said Sir Menelas Pangalos, Ph.D., independent member of the Antares Board. “I look forward to partnering with the Antares team as they address some of the most complex challenges in science.”

“Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development,” said Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center. “This team has demonstrated an ability to break through longstanding limits in medicinal chemistry to advance a pipeline of first-in-class assets, aiming to change the treatment landscape for patients.”

About Antares Therapeutics

Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need. Antares’ most advanced program is expected to enter the clinic in 2026, with multiple additional programs in preclinical development. To learn more, visit www.antaresrx.com and follow us on LinkedIn.

Media Contact:
Emily Anderson
emily.anderson@antaresrx.com

Investor Contact:
Danielle Dudgeon
Precision AQ
danielle.dudgeon@precisionaq.com

Categories: News

Tags: